Unguentum M Cream

Almirall Limited🇬🇧 Electronic Medicines Compendium

Approval Date: N/A
Approval ID: 8b03aeaaafa9c5f5
Company: Almirall Limited
Type: Standard

Approval Details

Approval Id: 8b03aeaaafa9c5f5
Drug Approval Emc Name: Unguentum M Cream
Drug Name: Unguentum M Cream
Company Name: Almirall Limited
Company Address: Almirall Limited, Harman House, 1 George Street, Uxbridge, Middlesex, UB8 1QQ, UK
Company Website: //www.almirall.co.uk
Company Telephone: 0800 0087399
Legal Category: General Sales List
Authorisation Holder: Almirall Hermal GmbH Scholtzstrasse 3 D-21465 Reinbek Germany
Authorisation Number: PL 33016/0014
Authorisation Date: 12/09/2005
Instruction Authorisation Holder: Almirall Hermal GmbH Scholtzstrasse 3 D-21465 Reinbek Germany
Instruction Authorisation Number: PL 33016/0014
Instruction Authorisation Date: 12/09/2005
Instruction Composition: There is no specific active ingredient. \*\*Excipients with known effect:\*\* Sorbic acid (E200) – 2 mg/g Cetosterearyl alcohol – 90 mg/g Propylene glycol (E1520) – 50 mg/g Buthylhydroxytoluene (E321) contained in white soft paraffin For full list of excipients, see section 6.1.
Instruction Dosage Form: Cream
Instruction Clinical Particulars: 4.1 Therapeutic indications Unguentum M has emollient properties and is recommended for the symptomatic treatment of dermatitis, nappy rash, ichthyosis, eczema, protection of raw and abraded skin areas, pruritus and related skin conditions where dry scaly skin is a problem, and as a pre-bathing emollient for dry/eczematous skin, to alleviate drying effects. Unguentum M is to be used as a diluent for various topical corticosteriod formulations in those instances where a lower strength preparation is considered desirable by the physician and as a general base for extemporaneous dispensing.4.2 Posology and method of administration \*\*Posology\*\* A thin application of the cream should be gently massaged into the skin three times daily or at appropriate intervals. When used as a protective cream Unguentum M should be applied sparingly to the affected areas of the skin before, or immediately after, exposure to a potentially harmful factor.4.3 Contraindications Unguentum M should not be used: - if hypersensitivity to any of the ingredients listed in section 6.1 is known. - near the eyes and on mucous membranes.4.4 Special warnings and precautions for use Sorbic acid (E200) and Cetostearyl alcohol may cause local skin reactions, (e.g. contact dermatitis) Propylene glycol (E1520) may cause skin reactions. White soft paraffin contains buthylhydroxytoluene (E321) and may cause local skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. Ingestion of Unguentum M should be avoided. Fire Hazard with emollients Instruct patients not to smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.4.5 Interaction with other medicinal products and other forms of interaction None.4.6 Fertility, pregnancy and lactation No evidence of any harmful effect on the use of Unguentum M in pregnancy and lactation.4.7 Effects on ability to drive and use machines None.4.8 Undesirable effects Rarely (1 in 10 out of 10,000 persons treated) skin irritation such as burning sensations and reddening or allergic contact dermatitis may occur. \*\*Reporting of suspected adverse reactions\*\* Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose None.
Instruction Pharmacology: 5.1 Pharmacodynamic properties Unguentum M is an ambiphilic topical preparation with emollient properties which maintains the high lipid content of an ointment but also has the water miscible characteristics of a cream. The high lipid content reduces water loss from the skin and therefore has a hydrating effect which permits the recovery from dermatitis, eczema, and dry or scaly skin conditions. Unguentum M also contains sorbic acid which has an antibacterial effect.5.2 Pharmacokinetic properties Unguentum M is for topical use only and contains no specific active ingredient. There are no phamacokinetic data for this product.5.3 Preclinical safety data --
Instruction Pharmaceutical Particulars: 6.1 List of excipients Purified water, white soft paraffin (contains buthylhydroxytoluene (E321)), cetostearyl alcohol, polysorbate 40, propylene glycol (E1520), glycerol monostearate 40 – 55, liquid paraffin, medium-chain triglycerides, sorbic acid (E200), colloidal anhydrous silica, sodium hydroxide.6.2 Incompatibilities None.6.3 Shelf life Aluminium tubes: 5 years Plastic containers: 3 years After first opening, use within 6 months.6.4 Special precautions for storage None.6.5 Nature and contents of container Aluminium tubes. Content: 10g, 15g, 30g, 50g, 60g, 80g and 100g. Plastic jars. Content: 500g. Plastic pump dispensers. Content: 200ml.6.6 Special precautions for disposal and other handling None.
Instruction Content: ## Composition There is no specific active ingredient. \*\*Excipients with known effect:\*\* Sorbic acid (E200) – 2 mg/g Cetosterearyl alcohol – 90 mg/g Propylene glycol (E1520) – 50 mg/g Buthylhydroxytoluene (E321) contained in white soft paraffin For full list of excipients, see section 6.1. ## Pharmaceutical Form Cream ## Clinical Particulars 4.1 Therapeutic indications Unguentum M has emollient properties and is recommended for the symptomatic treatment of dermatitis, nappy rash, ichthyosis, eczema, protection of raw and abraded skin areas, pruritus and related skin conditions where dry scaly skin is a problem, and as a pre-bathing emollient for dry/eczematous skin, to alleviate drying effects. Unguentum M is to be used as a diluent for various topical corticosteriod formulations in those instances where a lower strength preparation is considered desirable by the physician and as a general base for extemporaneous dispensing.4.2 Posology and method of administration \*\*Posology\*\* A thin application of the cream should be gently massaged into the skin three times daily or at appropriate intervals. When used as a protective cream Unguentum M should be applied sparingly to the affected areas of the skin before, or immediately after, exposure to a potentially harmful factor.4.3 Contraindications Unguentum M should not be used: - if hypersensitivity to any of the ingredients listed in section 6.1 is known. - near the eyes and on mucous membranes.4.4 Special warnings and precautions for use Sorbic acid (E200) and Cetostearyl alcohol may cause local skin reactions, (e.g. contact dermatitis) Propylene glycol (E1520) may cause skin reactions. White soft paraffin contains buthylhydroxytoluene (E321) and may cause local skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. Ingestion of Unguentum M should be avoided. Fire Hazard with emollients Instruct patients not to smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.4.5 Interaction with other medicinal products and other forms of interaction None.4.6 Fertility, pregnancy and lactation No evidence of any harmful effect on the use of Unguentum M in pregnancy and lactation.4.7 Effects on ability to drive and use machines None.4.8 Undesirable effects Rarely (1 in 10 out of 10,000 persons treated) skin irritation such as burning sensations and reddening or allergic contact dermatitis may occur. \*\*Reporting of suspected adverse reactions\*\* Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose None. ## Pharmacological Properties 5.1 Pharmacodynamic properties Unguentum M is an ambiphilic topical preparation with emollient properties which maintains the high lipid content of an ointment but also has the water miscible characteristics of a cream. The high lipid content reduces water loss from the skin and therefore has a hydrating effect which permits the recovery from dermatitis, eczema, and dry or scaly skin conditions. Unguentum M also contains sorbic acid which has an antibacterial effect.5.2 Pharmacokinetic properties Unguentum M is for topical use only and contains no specific active ingredient. There are no phamacokinetic data for this product.5.3 Preclinical safety data -- ## Pharmaceutical Particulars 6.1 List of excipients Purified water, white soft paraffin (contains buthylhydroxytoluene (E321)), cetostearyl alcohol, polysorbate 40, propylene glycol (E1520), glycerol monostearate 40 – 55, liquid paraffin, medium-chain triglycerides, sorbic acid (E200), colloidal anhydrous silica, sodium hydroxide.6.2 Incompatibilities None.6.3 Shelf life Aluminium tubes: 5 years Plastic containers: 3 years After first opening, use within 6 months.6.4 Special precautions for storage None.6.5 Nature and contents of container Aluminium tubes. Content: 10g, 15g, 30g, 50g, 60g, 80g and 100g. Plastic jars. Content: 500g. Plastic pump dispensers. Content: 200ml.6.6 Special precautions for disposal and other handling None.

Active Ingredients

Approved

Quick Info

Agency

UK EMC

Country

🇬🇧

Approval ID

8b03aeaaafa9c5f5

Type

Standard

Back to UK EMC Approvals